Court Rules
All enforcement actions
Enforcement ActionLow Risk

CT AG Sues Triggered Brand Over Unapproved GLP-1 Drug Sales

Triggered BrandMay 21, 2025Connecticut Attorney General

Summary

Connecticut Attorney General William Tong filed a lawsuit against Triggered Brand for selling unapproved 'research grade' GLP-1 weight loss drugs directly to consumers without prescriptions or medical oversight, violating the Connecticut Unfair Trade Practices Act and pharmacy licensing laws. The AG also issued a Civil Investigative Demand to Made In China for similar sales and sent warning letters to weight loss clinics about compounded GLP-1 drugs.

Remedy

The lawsuit seeks civil penalties of up to $5,000 per violation for selling unapproved drugs without a pharmacy license and engaging in unfair trade practices.

Monetary Penalty

Contract Impact

In-house legal teams should review vendor and supplier agreements to ensure partners hold valid pharmacy licenses, only distribute FDA-approved drugs, mandate prescriptions for prescription medications, and prohibit the sale of 'research-grade' or unapproved compounds for human consumption. Contracts should include compliance with state unfair trade practices laws, robust product safety and labeling requirements, and restrictions on deceptive marketing of compounded or counterfeit medications.

Contract Search Terms

prescription requirementFDA approvalpharmacy licensedrug distributionconsumer safetyunfair trade practicescompounded drugsresearch chemicalsweight loss drugsGLP-1 peptides

Laws Cited

Connecticut Unfair Trade Practices Actstatutes prohibiting the practice of pharmacy without a license

Violation Types

Entity Details

Entity

Triggered Brand

Industry

Healthcare

Official Sources

Source Evidence

Entity Name
"Triggered Brand"
Laws Cited
"Connecticut Unfair Trade Practices Act"
Laws Cited
"statutes prohibiting the practice of pharmacy without a license"
Violation Types
"sell 'research grade' GLP-1 peptides direct to Connecticut consumers for weight loss without prescriptions or any medical oversight"

Related Enforcement Actions

CT

U.S. Food and Drug Administration (FDA)

On May 11, 2026, Connecticut Attorney General William Tong led a bipartisan coalition of 21 attorneys general in submitting a comment letter to the U.S. Food and Drug Administration (FDA) urging the agency to abandon draft guidance that would ease approvals for flavored e-cigarette products. The coalition argues the guidance ignores evidence that flavored e-cigarettes disproportionately drive youth addiction and that FDA has failed to enforce existing authorization requirements for e-cigarette products. The letter references past tobacco and e-cigarette enforcement actions, including the 1998 tobacco master settlement agreement and the 2022 $438.5 million settlement with JUUL Labs.

CT

Bad actor platforms

Connecticut’s legislature passed House Bill 5312, creating new civil enforcement mechanisms for deepfake digital sexual assault, including unauthorized dissemination of synthetically created intimate images and AI-generated child pornography. The bill establishes a private right of action for victims and empowers the Connecticut Attorney General to pursue civil injunctions and penalties against abusers and platforms hosting illegal content. This builds on prior Connecticut laws criminalizing unauthorized intimate image dissemination.

CT

None

Connecticut Attorney General William Tong praised final passage of House Bill 5312, which creates new civil enforcement mechanisms for deepfake digital sexual assault. The legislation allows the AG to pursue civil injunctions and penalties against platforms that disseminate illegal synthetic intimate images, including AI-generated child pornography, and establishes a private right of action for victims. The bill builds on prior Connecticut laws criminalizing unauthorized dissemination of intimate images.

CT

Made-in-China

$300K

Connecticut Attorney General William Tong announced a settlement with international trade platform Made-in-China to cease all U.S. sales of unlawful 'research grade' GLP-1 weight loss drugs following an investigation into direct sales to consumers without prescriptions or medical oversight. The settlement prohibits the platform from hosting GLP-1 sales to U.S. customers, requires a monitoring system to remove non-compliant listings, and imposes a $300,000 penalty suspended after an initial $30,000 payment. Additional settlements were announced with Radiance Medspa and Advanced Medical Weight Loss over compounded non-FDA approved GLP-1 drugs.

CT

social media companies

Connecticut Attorney General William Tong issued a statement on May 1, 2026, announcing the final passage of bipartisan legislation targeting youth social media addiction and artificial intelligence harms. The legislation imposes new obligations on social media companies regarding minor account settings, parental consent, and reporting, as well as requirements for AI chatbot operators and employers using automated decision tools. The statement also references ongoing enforcement actions against Meta and TikTok for allegedly designing addictive platform features for youth.

CT

Office of the Attorney General William Tong

Connecticut Attorney General William Tong issued a statement on May 1, 2026, following final passage of bipartisan legislation to combat youth social media addiction and regulate artificial intelligence harms. The legislation imposes new requirements on social media companies regarding minor users, including parental consent for addictive algorithms, default privacy settings, and annual reporting obligations. It also establishes rules for AI chat bots and automated employment decision tools, including disclosure requirements and self-harm detection protocols.